1 reports of this reaction
3.6% of all GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 reports
#16 most reported adverse reaction
HOSPITALISATION is the #16 most commonly reported adverse reaction for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, manufactured by CVS Pharmacy. There are 1 FDA adverse event reports linking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 to HOSPITALISATION. This represents approximately 3.6% of all 28 adverse event reports for this drug.
Patients taking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is moderately reported among GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 users, representing a notable but not dominant share of adverse events.
In addition to hospitalisation, the following adverse reactions have been reported for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1 FDA reports for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 3.6% of all adverse event reports for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, making it a notable side effect.
If you experience hospitalisation while taking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.